Market Place
Sourcing Support
CureVac to Report Q3 & 9-Month 2024 Results on Nov 12, 2024
07 Nov 2024 //
ACCESSWIRE
CureVac to Present at SITC 39th Annual Meeting
28 Oct 2024 //
ACCESSWIRE
Pfizer, BioNTech win bid to invalidate CureVac`s vaccine patents
08 Oct 2024 //
REUTERS
CureVac`s CVGBM Vaccine Shows Promise In Glioblastoma At ESMO 2024
13 Sep 2024 //
ACCESSWIRE
British drugmaker GSK moves mRNA flu vaccine to late-stage trials
13 Sep 2024 //
REUTERS
GSK Reports Positive Phase 2 Data For mRNA Flu Vaccine With CureVac
12 Sep 2024 //
ACCESSWIRE
CureVac To Present CVGBM Data At ESMO 2024
09 Sep 2024 //
ACCESSWIRE
CureVac Updates On Patent Litigation Trial Dates Against Pfizer/BioNTech
11 Jul 2024 //
ACCESSWIRE
Agomab Appoints Pierre Kemula As Chief Financial Officer
11 Jul 2024 //
BUSINESSWIRE
GSK buys full rights to make COVID, influenza vaccines from CureVac
03 Jul 2024 //
REUTERS
CureVac Announces Voting Results Of General Meeting
24 Jun 2024 //
ACCESSWIRE
CureVac: First Patient Dosed In Phase 2 Seasonal Flu Study With GSK
28 May 2024 //
ACCESSWIRE
Curevac Q1 2024 Financials: Business Update Provided By Company
23 May 2024 //
ACCESSWIRE
CureVac to cut costs, starts GSK-partnered bird flu vaccine trial
24 Apr 2024 //
ENDPTS
CureVac Starts H5N1 Flu Phase 1/2 with GSK
24 Apr 2024 //
ACCESSWIRE
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
24 Apr 2024 //
ACCESSWIRE
CureVac Reports Q4 & 2023 Results, Business Update
24 Apr 2024 //
ACCESSWIRE
CureVac To Report Q4 2023 Results On April 24
18 Apr 2024 //
ACCESSWIRE
CureVac, MD Anderson Enter Strategic Cancer Vax Pact
17 Apr 2024 //
PRESS RELEASE
CureVac and MD Anderson Collaborate on Novel Cancer Vaccine Development
16 Apr 2024 //
ACCESSWIRE
CureVac Announces Ph 2 Interim Data from Seasonal Influenza Vaccine with GSK
05 Apr 2024 //
PRESS RELEASE
CureVac Announces Promising Ph 2 Data from Influenza Program in Collab with GSK
04 Apr 2024 //
ACCESSWIRE
CureVac Announces Positive Ph 2 Data from Vaccine Development Program
05 Jan 2024 //
ACCESSWIRE
CureVac touts COVID-19 vax data despite adverse events
05 Jan 2024 //
FIERCE BIOTECH
German court quashes CureVac patent after challenge by BioNTech
20 Dec 2023 //
REUTERS
CureVac Announces Financial Results for the Third Quarter
14 Nov 2023 //
ACCESSWIRE
CureVac Announces Progress in Ph 2 COVID-19 & Seasonal Flu Development Programs
01 Nov 2023 //
ACCESSWIRE
CureVac touts `progress` in vaccine patent case against BioNTech
28 Sep 2023 //
FIERCE PHARMA
CureVac hand-picks mRNA flu vaccine but keeps data tucked away
12 Sep 2023 //
FIERCE BIOTECH
CureVac Announces Financial Results for the Second Quarter
17 Aug 2023 //
ACCESSWIRE
CureVac Announces Dosing of First Participant in Phase 2 Study of COVID-19 mRNA Vaccine Candidates
01 Aug 2023 //
ACCESSWIRE
LimmaTech regains Shigella shot from GSK, new CEO from CureVac
20 Jul 2023 //
FIERCE BIOTECH
CureVac Announces Update to the Management Team
14 Jul 2023 //
ACCESSWIRE
CureVac expands COVID-19 patent cases against Pfizer, BioNTech
14 Jul 2023 //
FIERCE PHARMA
CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate
20 Jun 2023 //
ACCESSWIRE
CureVac Announces Financial Results for the First Quarter of 2023
30 May 2023 //
ACCESSWIRE
CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech
20 May 2023 //
ACCESSWIRE
GSK, CureVac initiate new Phase I/II trial of mRNA flu vaccine
08 May 2023 //
CLINICAL TRIALS ARENA
CureVac Announces Financial Results for the 4Q Full-Year 2022
25 Apr 2023 //
ACCESSWIRE
CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results
18 Apr 2023 //
ACCESSWIRE
CureVac Announces Voting Results of Extraordinary General Meeting
28 Mar 2023 //
ACCESSWIRE
CureVac Announces Closing of $250M Follow-on Public Offering of Common Shares
10 Feb 2023 //
ACCESSWIRE
CureVac Announces Proposed Public Offering of Common Shares
07 Feb 2023 //
ACCESSWIRE
CureVac Welcomes Myriam Mendila as New Chief Development Officer
01 Feb 2023 //
ACCESSWIRE
CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis(R)
31 Jan 2023 //
ACCESSWIRE
CureVac Announces Positive Data in Older Adults from COVID-19 Vaccine Programs
30 Jan 2023 //
ACCESSWIRE
New CEOs for Covid vaccine makers CureVac and Novavax
10 Jan 2023 //
ENDPTS
CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Programs
06 Jan 2023 //
PRESS RELEASE
CureVac Members of Management Sell Shares to Cover Tax Obligations
14 Dec 2022 //
ACCESSWIRE
CureVac rethinks lead cancer program after posting PD-1 data
17 Nov 2022 //
FIERCEBIOTECH
CureVac Announces Financial Results for the Third Quarter
16 Nov 2022 //
ACCESSWIRE
CureVac Presents Preliminary Data from Phase 1 Study Expansion Oncology CV8102
11 Nov 2022 //
ACCESSWIRE
Pfizer, BioNTech seek to revoke CureVac`s patent infringement claims
02 Sep 2022 //
REUTERS
CureVac Starts PI Study of Modified, Omicron-Targeting COVID-19 Vaccine
18 Aug 2022 //
ACCESSWIRE
CureVac Announces Financial Results for Q2 and H1 of 2022
18 Aug 2022 //
ACCESSWIRE
CureVac, GSK load into starting block in omicron booster race
18 Aug 2022 //
FIERCEBIOTECH
Pfizer and BioNTech contest CureVac COVID shot patent charges
27 Jul 2022 //
FIERCEPHARMA
BioNTech could owe CureVac $500M in royalties if suit succeeds
12 Jul 2022 //
FIERCEPHARMA
CureVac files patent lawsuit in Germany against BioNTech over mRNA tech
06 Jul 2022 //
BUSINESS-STANDARD
CureVac inks biotech buyout to step up cancer vaccine R&D
10 Jun 2022 //
FIERCEBIOTECH
